Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.44 |
| ▸ | HTR3B | O95264 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12075159 | 0.81 | MKNK1 (0.46) | CYP1A2MKNK1MKNK2MAPK8MAPK9 | |
| SCHEMBL18418488 | 0.76 | HRH3 (0.42) | HRH3ALDH1A1KDM4ECYP1A2HTR3E | |
| SCHEMBL14668886 | 0.76 | CCR1 (0.48) | KDM4ETDP1CYP3A4HTTPMP22 | |
| SCHEMBL12075537 | 0.73 | IRAK4 (0.57) | ALDH1A1KDM4ECYP1A2MKNK1MKNK2 | |
| SCHEMBL31020506 | 0.73 | IRAK4 (0.57) | ALDH1A1KDM4ECYP1A2MKNK1MKNK2 | |
| SCHEMBL18797697 | 0.72 | MKNK1 (0.38) | ALDH1A1CYP1A2MKNK1MKNK2MAPK8 | |
| SCHEMBL12489602 | 0.71 | CDC7 (0.56) | MKNK1MKNK2MAPK8MAPK9MAPK10 | |
| SCHEMBL17683140 | 0.71 | MKNK1 (0.51) | KDM4EMKNK1MKNK2MAPK8MAPK9 | |
| SCHEMBL30459875 | 0.71 | MKNK1 (0.51) | KDM4EMKNK1MKNK2MAPK8MAPK9 | |
| SCHEMBL729956 | 0.71 | KDM4E (0.56) | ALDH1A1KDM4ECYP1A2HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20120108499-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2012-05-03 | — | — | US | disclosed |
| EP-2343285-A2 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-07-13 | — | — | EP | disclosed |
| US-20100167995-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2010-07-01 | — | — | US | disclosed |
| US-7612036-B2 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2009-11-03 | — | — | US | disclosed |
| EP-1412336-A4 | PEPTOID COMPOUNDS | UNIV WOLLONGONG (AU) | 2007-08-29 | — | — | EP | disclosed |
| US-20070111927-A1 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2007-05-17 | — | — | US | disclosed |
| US-7160854-B2 | Binaphthyl peptidomimetics for treating vancomycin resistant Staphylococcus aureas infections | UNIVERSITY OF WOLLONGONG (AU) | 2007-01-09 | — | — | US | disclosed |
| US-20050043509-A1 | Peptoid compounds | UNIVERSITY OF WOLLONGONG | 2005-02-24 | — | — | US | disclosed |
| EP-1412336-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002545-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108499-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | HRH3 3200/4885ALDH1A1 4540/4885KDM4E 4594/4885 |
| US-20100167995-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | HRH3 3200/4885ALDH1A1 4540/4885KDM4E 4594/4885 |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | HRH3 2280/4885ALDH1A1 2387/4885KDM4E 3361/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | HRH3 2280/4885ALDH1A1 2387/4885KDM4E 3361/4885 |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | HRH3 2280/4885ALDH1A1 2387/4885KDM4E 3361/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | HRH3 2280/4885ALDH1A1 2387/4885KDM4E 3361/4885 |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | HRH3 2280/4885ALDH1A1 2387/4885KDM4E 3361/4885 |
| US-20070111927-A1 | Peptoid compounds | VIP, FPR1, VIPR1 | HRH3 3200/4885ALDH1A1 4540/4885KDM4E 4594/4885 |
| US-20050043509-A1 | Peptoid compounds | VIP, FPR1, VIPR1 | HRH3 3200/4885ALDH1A1 4540/4885KDM4E 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.